Patricia Gomez-Bougie

Patricia Gomez-Bougie

Auto-generated profile, based on publicly available information

Patricia Gomez-Bougie

Nantes Université, CHU Nantes, CNRS, INSERM, CRCI2NA, Université d’Angers, Nantes, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Cancer Research
Verified
Journal Article
Closed access
PDF file
PGPatricia Gomez-Bougie
Patricia Gomez-Bougie
SWSoraya WuillèmE-Toumi
Soraya WuillèmE-Toumi
EMEmmanuelle MénOret
Emmanuelle MénOret
VTValérIe Trichet
ValérIe Trichet
NRNelly Robillard
Nelly Robillard
MAMartine Amiot
Martine Amiot
Targeting the ubiquitin-proteasome pathway has emerged as a potent anticancer strategy. Bortezomib, a specific proteasome inhibitor, has been approved for the treatment of relapsed or refractory multiple myeloma. Multiple myeloma cell survival is highly dependent on Mcl-1 antiapoptotic molecules. In a recent study, proteasome inhibitors induced Mcl-1 accumulation that slowed down their proapoptotic effects. Consequently, we investigated the role of Bcl-2 family members in bortezomib-induced apoptosis. We found that bortezomib induced apoptosis in five of seven human myeloma cell lines (HMCL). Bortezomib-induced apoptosis was associated with Mcl-1 cleavage regardless of Mcl-1L accumulation. Furthermore, RNA interference mediated Mcl-1 decrease and sensitized RPMI-8226 HMCL to bortezomib, highlighting the contribution of Mcl-1 in bortezomib-induced apoptosis. Interestingly, an important induction of Noxa was found in all sensitive HMCL both at protein and mRNA level. Concomitant to Mcl-1 cleavage and Noxa induction, we also found caspase-3, caspase-8, and caspase-9 activation. Under bortezomib treatment, Mcl-1L/Noxa complexes were highly increased, Mcl-1/Bak complexes were disrupted, and there was an accumulation of free Noxa. Finally, we observed a dissociation of Mcl-1/Bim complexes that may be due to a displacement of Bim induced by Noxa. Thus, in myeloma cells, the mechanistic basis for bortezomib sensitivity can be explained mainly by the model in which the sensitizer Noxa can displace Bim, a BH3-only activator, from Mcl-1, thus leading to Bax/Bak activation. [Cancer Res 2007;67(11):5418–24]

6 October 2011 in Blood
Verified
Journal Article
Open access
PDF file
LBLinda Bodet
Linda Bodet
PGPatricia Gomez-Bougie
Patricia Gomez-Bougie
CTCyrille Touzeau
Cyrille Touzeau
CDChristelle Dousset
Christelle Dousset
GDGéraldine Descamps
Géraldine Descamps
MAMartine Amiot
Martine Amiot
Multiple myeloma is a plasma cell malignancy that is heterogeneous with respect to its causative molecular abnormalities and the treatment response of patients. The Bcl-2 protein family is critical for myeloma cell survival. ABT-737 is a cell-permeant compound that binds to Bcl-2 and Bcl-xL but not to Mcl-1. Using a myeloma cell line collection (n = 25) representative of different molecular translocations, we showed that ABT-737 effectively kills a subset of cell lines (n = 6), with a median lethal dose ranging from 7 ± 0.4nM to 150 ± 7.5nM. Of interest, all sensitive cell lines harbored a t(11;14). We demonstrated that ABT-737–sensitive and ABT-737–resistant cell lines could be differentiated by the BCL2/MCL1 expression ratio. A screen of a public expression database of myeloma patients indicates that the BCL2/MCL1 ratio of t(11;14) and hyperdiploid patients was significantly higher than in all other groups (P < .001). ABT-737 first induced the disruption of Bcl-2/Bax, Bcl-2/Bik, or Bcl-2/Puma complexes, followed by the disruption of Bcl-2 heterodimers with Bak and Bim. Altogether, the identification of a subset of cell lines and primary cells effectively killed by ABT-737 alone supported the evaluation of ABT-263, an orally active counterpart to ABT-737, for the treatment of t(11;14) and hyperdiploid groups of myeloma harboring a Bcl-2high/Mcl-1low profile.

13 August 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JHJonathan M. Harnoss
Jonathan M. Harnoss
ATAdrien Le Thomas
Adrien Le Thomas
ASAnna Shemorry
Anna Shemorry
SMScot A. Marsters
Scot A. Marsters
DLDavid A. Lawrence
David A. Lawrence
AAAvi Ashkenazi
Avi Ashkenazi
Multiple myeloma (MM) arises from malignant immunoglobulin (Ig)-secreting plasma cells and remains an incurable, often lethal disease despite therapeutic advances. The unfolded-protein response sensor IRE1α supports protein secretion by deploying a kinase–endoribonuclease module to activate the transcription factor XBP1s. MM cells may co-opt the IRE1α–XBP1s pathway; however, the validity of IRE1α as a potential MM therapeutic target is controversial. Genetic disruption of IRE1α or XBP1s, or pharmacologic IRE1α kinase inhibition, attenuated subcutaneous or orthometastatic growth of MM tumors in mice and augmented efficacy of two established frontline antimyeloma agents, bortezomib and lenalidomide. Mechanistically, IRE1α perturbation inhibited expression of key components of the endoplasmic reticulum-associated degradation machinery, as well as secretion of Ig light chains and of cytokines and chemokines known to promote MM growth. Selective IRE1α kinase inhibition reduced viability of CD138+ plasma cells while sparing CD138− cells derived from bone marrows of newly diagnosed or posttreatment-relapsed MM patients, in both US- and European Union-based cohorts. Effective IRE1α inhibition preserved glucose-induced insulin secretion by pancreatic microislets and viability of primary hepatocytes in vitro, as well as normal tissue homeostasis in mice. These results establish a strong rationale for developing kinase-directed inhibitors of IRE1α for MM therapy. Significance Multiple myeloma (MM) is a lethal malignancy arising from plasma cells. MM cells experience endoplasmic reticulum (ER) stress due to immunoglobulin hyperproduction. The ER-resident sensor IRE1α mitigates ER stress by expanding protein-folding and secretion capacity, while supporting proteasomal degradation of ER misfolded proteins. IRE1α elaborates these functions by deploying a cytoplasmic kinase–RNase module to activate the transcription factor XBP1s. Although IRE1α has been implicated in MM, its validity as a potential therapeutic target—particularly as a kinase—has been unclear. Using genetic and pharmacologic disruption, we demonstrate that the IRE1α–XBP1s pathway is critical for MM tumor growth. We further show that the kinase domain of IRE1α is an effective and safe potential small-molecule target for MM therapy.

1 September 2011 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
PGPatricia Gomez-Bougie
Patricia Gomez-Bougie
EMEmmanuelle Ménoret
Emmanuelle Ménoret
PJPhilippe Juin
Philippe Juin
CDChristelle Dousset
Christelle Dousset
CPCatherine Pellat-deceunynck
Catherine Pellat-deceunynck
MAMartine Amiot
Martine Amiot

20 December 2018 in Blood
Verified
Journal Article
Closed access
PDF file
PGPatricia Gomez-Bougie
Patricia Gomez-Bougie
SMSophie Maiga
Sophie Maiga
BTBenoit Tessoulin
Benoit Tessoulin
JBJessie Bourcier
Jessie Bourcier
ABAntoine Bonnet
Antoine Bonnet
MAMartine Amiot
Martine Amiot
BH3 mimetics are promising drugs for hematologic malignancies that trigger cell death by promoting the release of proapoptotic BCL2 family members from antiapoptotic proteins. Multiple myeloma is considered to be a disease dependent mainly on MCL1 for survival, based mostly on studies using cell lines. We used a BH3-mimetic toolkit to study the dependency on BCL2, BCLXL, or MCL1 in malignant plasma cells from 60 patients. Dependencies were analyzed using an unbiased BH3 mimetics cell-death clustering by k-means. In the whole cohort of patients, BCL2 dependency was mostly found in the CCND1 subgroup (83%). Of note, MCL1 dependence significantly increased from 33% at diagnosis to 69% at relapse, suggesting a plasticity of the cellular dependency favoring MCL1 dependencies at relapse. In addition, 35% of overall patient samples showed codependencies on either BCL2/MCL1 or BCLXL/MCL1. Finally, we identified a group of patients not targeted by any of the BH3 mimetics, predominantly at diagnosis in patients not presenting the common recurrent translocations. Mechanistically, we demonstrated that BAK is crucial for cell death induced by MCL1 mimetic A1210477, according to the protection from cell death observed by BAK knock-down, as well as the complete and early disruption of MCL1/BAK complexes on A1210477 treatment. Interestingly, this complex was also dissociated in A1210477-resistant cells, but free BAK was simultaneously recaptured by BCLXL, supporting the role of BCLXL in A1210477 resistance. In conclusion, our study opens the way to rationally use venetoclax and/or MCL1 BH3 mimetics for clinical evaluation in myeloma at both diagnosis and relapse.

30 September 2004 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
PGPatricia Gomez‐Bougie
Patricia Gomez‐Bougie
RBRégis Bataille
Régis Bataille
MAMartine Amiot
Martine Amiot
Multiple myeloma is a fatal B cell malignancy characterized by the accumulation of plasma cells within the bone marrow. IL‐6 is a major survival factor for myeloma cells. Bcl‐2 protein family regulates pathways to apoptosis that are activated upon growth factor deprivation. Pro‐apoptotic proteins that have only a single Bcl‐2 homology domain, BH3‐only, are potent inducers of apoptosis. In myeloma cells, Mcl‐1 has been shown to be a major anti‐apoptotic protein that appears to regulate cell survival through the JAK/STAT pathway. In this study, we examined the regulation of the BH3‐only protein Bim and its interaction with Mcl‐1. The three major Bim isoforms are expressed in myeloma cells and are negatively regulated by IL‐6. Blockade of IL‐6 signaling induces an up‐regulation of Bim concomitant to Mcl‐1 down‐regulation. Of major interest, Bim is found strongly associated with Mcl‐1 in viable myeloma cells while this interaction is disrupted under apoptosis induction. Of note, while Bim is also found strongly associated to Bcl‐2, this interaction is not changed under apoptosis induction. Thus, in myeloma cells, Mcl‐1 neutralizes Bim through complex formation and therefore prevents apoptosis. Under apoptosis induction, the disappearance of Mcl‐1 allows Bim to exercise its pro‐apoptotic function and to activate Bax.